San Diego-based Sangart has gone missing in action after apparently burning through more than a quarter-billion dollars of Leucadia National cash.
The seventh-round financing is expected to fuel development of San Diego-based Sangart's treatments that deliver essential gases to embattled tissues.
Investors have anted up $50 million to back Sangart's ambitious effort to develop a molecule that can carry badly needed oxygen to various tissue targets in the body. Leucadia National Corporation
San Diego-based Sangart has raised $50 million from its Series F. The money comes from the exercise of warrants issued in 2007 and it brings the total amount of cash raised in the investment round to
San Diego-based Sangart is restructuring, triggering a "significant reduction in work force" as it names four new additions to its executive staff. The executive changes include the appointment of